NCT04433858View on ClinicalTrials.gov

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

June 1, 2025

Study Completion Date

May 1, 2026

Conditions

Treatment Resistant Depression

Interventions

DRUG

Psilocybin

open-label

Trial Locations (2)

21204

Sheppard Pratt Health System, Baltimore

94304

VA Palo Alto Healthcare System/Stanford Medicine, Palo Alto

Sponsors

Collaborators (1)

COMPASS Pathways

All Listed Sponsors

collaborator

COMPASS Pathways

INDUSTRY

lead

Sheppard Pratt Health System

OTHER